Newsletter · 2026-09-07 · Ashutosh Agarwal

Courts End Mass GLP-1 Compounding as Mounjaro Wins a Heart Indication - The Obesity-Drug Pipeline - Week of September 7, 2026

The Obesity-Drug Pipeline for the week of September 7, 2026: the Fifth Circuit upheld the FDA and legally ended 503B mass compounding of tirzepatide and semaglutide, Mounjaro won a cardiovascular indication off a 13,000-patient trial, and the payer squeeze got named logos as Starbucks and PepsiCo pulled back while 600,000 seniors signed up for Medicare's 50 dollar a month program.

The Obesity-Drug Pipeline

Week of September 7, 2026: The Courts Just Ended Mass GLP-1 Compounding

TL;DR

• A federal appeals court shut the door on mass-produced knockoff GLP-1s. On August 27, the Fifth Circuit Court of Appeals upheld the FDA's decision to pull Lilly's and Novo's drugs off the official shortage list, which legally ends "503B" mass compounding of tirzepatide and semaglutide. Individualized pharmacy compounding for a specific patient (503A) survives. The cheap-copy channel that has capped branded pricing for two years just got a lot narrower (On The Pen GLP-1 News).
• Lilly's Mounjaro won a new heart-disease approval, and CEO Dave Ricks did a victory lap on CNBC. The FDA cleared Mounjaro to cut cardiovascular death, heart attack, and stroke in high-risk type-2 diabetics, based on a 13,000-patient, four-year trial. Ricks said obesity and diabetes are now "about 65% of the company," with 25 to 30 million people worldwide already on Lilly's drugs "and more than a billion potential customers" (Squawk on the Street).
• The payer squeeze got real: employers are backing away while Washington leans in. Starbucks and PepsiCo were both named this week as dropping or scrutinizing obesity-drug coverage, calling it one of their fastest-growing health costs. Meanwhile 600,000+ seniors have already signed up for Medicare's new $50-a-month GLP-1 program, a fixed price against a list price of "over $1,000" (On The Pen GLP-1 News · Pharmacy Podcast Network).

What's new

The five developments most likely to move numbers or the thesis, ranked by how actionable they are for a book.

1. The Fifth Circuit ended mass compounding, the single biggest structural story of the week. The clearest, most investable news came from Dave Knapp, host of On The Pen GLP-1 News (September 2), a patient advocate and long-time GLP-1 commentator writing from outside the industry. On August 27, he explained, the Fifth Circuit Court of Appeals ruled in two separate lawsuits, one over Lilly's tirzepatide (Mounjaro/Zepbound), one over Novo's semaglutide (Ozempic/Wegovy), both brought by the Outsourcing Facilities Association and a company called Pharmacheo. The court upheld the FDA's determination to take those drugs off the shortage list, which, in Knapp's words, "put an end legally to 503B compounding of GLP-1s, mass producing of GLP-1s."

Why this matters for the book: for two years, compounding pharmacies exploited the official shortage designation to churn out cheap copies at scale, which put a ceiling on what Lilly and Novo could charge and quietly siphoned off volume. That mass channel is now legally closed. Knapp was careful about what did not change: "individualized… pharmacy compounding did not suddenly become illegal." Federal law still lets a pharmacy compound "custom dosing and custom formulations for patients who cannot tolerate the branded versions," that's the 503A carve-out, and it's the loophole the gray market will now try to hide inside. He also flagged an FDA website update tightening language on multi-dose vials ("should be used within 28 days after its first puncture"), though he stressed that's a longstanding sterility standard, not a new GLP-1-specific rule. Bottom line: a real, durable tailwind for branded pricing and volume, with a smaller, messier 503A back door left ajar.

2. Mounjaro gets a heart-disease label, and Dave Ricks lays out the whole Lilly story. This is the week's biggest company event, and it came from the one true insider on the feed. On Squawk on the Street (August 31), Eli Lilly Chair and CEO Dave Ricks discussed a new FDA indication, confirmed the same week by On The Pen, clearing Mounjaro "for reducing cardiovascular death, heart attack, and stroke in patients with type 2 diabetes who are at increased cardiovascular risk." The approval rests on the SURPASS cardiovascular outcomes trial, where, per Knapp, "more than 13,000 high-risk people with type 2 diabetes were followed for four years" and Mounjaro beat Trulicity, earning "the non-inferiority mark."

Ricks used the interview to frame the entire franchise. Obesity, weight loss, and diabetes are now "about 65% of the company," with Mounjaro and Zepbound the "huge drivers." On penetration: "three years into these medicines, we probably have 25, 30 million people globally on them. And there's more than a billion potential customers." On the pipeline, he said Lilly has "three phase three assets right now beyond… Zepbound and Mounjaro," naming next-generation drugs "like Retatrutide and Aluralintide" (an amylin-based drug) as the way to make "that obesity franchise more durable." He also confirmed a fresh deal, buying Morita Biosciences, "an early phase deal" whose most advanced program is a Phase 1 in autoimmune disease, and put Lilly's year-to-date M&A at "over $25 billion in announced deals." Most usefully for the payer debate, Ricks pushed back directly on the employer-coverage scare (see below): the coverage math "right now… it's about neutral," and he cited a recently published study showing that for Zepbound patients, "by year one, at 12 months, it was more than break even." A confident, numbers-heavy insider read that reinforces the Lilly-as-core-long story.

3. The employer backlash got names, and they're big ones. The bear's favorite worry finally has marquee logos attached. On On The Pen GLP-1 News (September 2), Knapp reported "Starbucks dropping obesity coverage for their employees" and, "last week, PepsiCo… telling employees that GLP-1 medications have essentially become one of the fastest growing expenses in their health care plan." His warning: "we could see a large scale pullback in employer sponsored plans actually covering obesity medicine." He also made a blunt pitch to the drugmakers: "Lily Novo, if it was ever a time to build some goodwill with the community, lower the prices now… bring them down to $250 for the top doses, even lower for the lower doses."

This is the core bear thread: if self-insured employers, who cover most working-age Americans, decide obesity drugs are too expensive, the commercial book shrinks no matter how good the science gets. Note the direct tension with Ricks's "more than break even by 12 months" study. The two sides are now openly arguing over the same employer-ROI math, in public. That debate is the swing factor for commercial volume over the next year.

4. Washington is filling the coverage gap, cheaply, and that cuts both ways. Two podcasts put hard numbers on Medicare's new GLP-1 Bridge program. HaVy Ngo-Hamilton, Senior Pharmacy Director at Buzz Health, walked through the mechanics on Pharmacy Podcast Network (September 4): the program runs "from July of this year until December of 2027," offering eligible Medicare members a "$50 a month fixed co-payment" against a "list price of over $1,000." But she flagged a catch that matters: the $50 "would not be counted toward your deductible" or out-of-pocket max, so it's "$50 times 12, that's $600 a year," and it runs "completely outside" the normal Part D benefit with "their own system to process prior authorization." On The Pen added the uptake number: "over 600,000 people have already enrolled" since the July 1 start.

The read-through is genuinely two-sided. It's bullish for volume, since the government just put a cheap, fixed price in front of a huge senior population that was previously locked out. But it's bearish for net price, because every script that shifts to a $50 fixed copay is a script no longer earning the commercial rebate spread. And it's temporary, sunsetting end-2027, which turns "will they extend it?" into a real 2027 catalyst.

5. India shows what "cheap and commoditized" actually looks like, and it's a warning. For a preview of the bear's endgame, look at India. On Daybreak (September 1), journalists Rachel Varghese and Nikita Sharma of The Ken reported that Novo's semaglutide patent expired in India in March 2026, "triggering release of 50+ generic variants." The result wasn't a boom, it was a fizzle. The whole Indian GLP-1 market did roughly "$220–$230 million in the year to May 2026"; a Nomura report had forecast 2026 sales would "cross $260 million," but "by July only 20% had been achieved." Monthly sales growth collapsed from "58.4% growth in April" to just "2% in June," because, per one industry executive, "all eligible patients have been onboarded… and fewer newer patients are starting this therapy."

Set that against the US, where "Ozempic alone generated roughly $12 billion in US revenue in 2025" and "one in five US households has at least one GLP-1 user." The contrast is the whole investment debate in one frame: in a market with no insurance scaffolding and instant generic competition, GLP-1s saturate fast and stay cheap. The bull says the US is different, patent-protected, insured, and label-expanding. The bear says India is a time machine. This week gave you both data points to argue it.

The debate

The bull case (steel-manned): This is now a heart-and-metabolism franchise with legal and regulatory wind at its back. The Fifth Circuit just closed the mass-compounding channel that was capping branded pricing, and Mounjaro's fresh cardiovascular approval, off a 13,000-patient, four-year trial, converts a weight-loss drug into guideline-driven, lifelong preventive medicine. Doctors this week went further: obesity treatment is "disease-modifying," and roughly 90% of US adults carry at least one cardiovascular-kidney-metabolic risk factor, so the addressable population keeps widening into liver disease, kidney disease, sleep apnea, and beyond. Penetration is already extraordinary, with a Gallup read of "11% currently" taking a weight-loss drug (up from 3% a year and a half ago) and "one in five US households." Lilly is compounding as the clear leader with 25 to 30 million patients, a billion-customer runway, three Phase 3 assets in reserve (retatrutide, aluralintide), $25B of deals done this year, and a published study showing employer coverage is "more than break even" by month 12. Medicare just handed the category 600,000 new seniors at $50 a month.

The bear case (steel-manned): Follow the price, not the volume. Named, blue-chip employers, Starbucks and PepsiCo, are now openly pulling back because GLP-1s are "one of the fastest growing expenses" in their plans, and that's the commercial book that actually pays full freight. Every alternative channel pushes net price down: Medicare's $50 fixed copay bypasses the rebate model, California is chasing $250 Medicaid pricing through CalRx, and the field is about to get crowded, with Donna Ryan expecting "at least 25 different medications" based on these hormone targets "by 2030," and CagriSema, retatrutide, orforglipron, and oral semaglutide all landing in the next 18 months. The product still leaks patients: "only about half" are still on therapy after a year, and those who quit "regain approximately two-thirds" of the weight, so the recurring-revenue story has a hole in it. And India is the cautionary tale: the moment the patent fell, 50+ generics appeared, growth crashed from 58% to 2% a month, and the market stalled at a fifth of forecast.

The honest read (a framing, not a call): This week finally gave the bull side two hard wins, a court ruling and an FDA approval, where before it had mostly soft clinical color. Structurally, supply (compounding) is tightening and the label (indications) is widening, both of which support the "durable, insured, lifelong" thesis. But the exact same week, the payer side hardened in the other direction, with real companies putting real logos on the pullback and Washington substituting a cheap fixed price for the commercial rebate. So the vectors are now both moving faster: volume-up and price-down are each accelerating, not converging. The number that would settle it is still the one nobody hands out cleanly, net revenue per patient per year, sustained through the discontinuation drop-off. Ricks's "more than break even by 12 months" study is the closest anyone came this week, and it's a company-sponsored data point in an argument with self-insured employers who clearly aren't buying it yet. Watch whether that study survives contact with the plan sponsors.

Stocks in play

Only two coverage-universe tickers were discussed by name this week: LLY (extensively, via Ricks and the compounding and CV-approval news) and NVO (via India generics, oral semaglutide, CagriSema, and the compounding case). Amgen, Viking, and Roche were not named at all, see Read-throughs.

Read-throughs

• Fast-followers (AMGN, VKTX, Roche): silent, for the third-plus week running. Not one episode this week named Amgen's MariTide, Viking Therapeutics or VK2735, or Roche's CT-388/CT-996. Even the comparative-efficacy discussions, which had a perfect opening to mention them, stuck entirely to Lilly and Novo assets (retatrutide, orforglipron, CagriSema, oral semaglutide). For a group whose whole thesis is "buyout optionality and next-gen efficacy," that is a mild negative on narrative momentum: the market's attention is consolidating on the two leaders.
• Contract manufacturing and fill-finish (CTLT, LNZA, TMO): quiet. No Western contract manufacturer was named. The one supply-side story that mattered was regulatory, not industrial, the Fifth Circuit compounding ruling, which is arguably a modest positive for the branded supply chain (more branded volume, less compounded), but no one connected that dot to a named CDMO this week.
• Pen and auto-injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize): silent again. No device supplier was mentioned. The structural drift toward oral pills, with oral semaglutide 25mg now approved and orforglipron being studied explicitly as an oral maintenance step-down from injectables via the ATTAIN/MAINTAIN studies, keeps quietly working against the injection-hardware names.
• Insurers, PBMs and employers (CVS, CI, UNH): the disintermediation and cost-pushback story is loud, even without the tickers. No PBM was named directly, but the week was full of read-throughs. Employers (Starbucks, PepsiCo) are pulling back; Medicare's Bridge program runs "completely outside" normal Part D with its own prior-auth system and a flat $50 copay that bypasses the rebate model; California wants CalRx to buy drugs directly at $250. Every one of those mechanisms routes around the traditional pharmacy-benefit middleman. The direction of travel, government and direct channels gaining share and commercial-rebate economics shrinking, is the thing to keep watching for the PBM-heavy names.
• Compounding and the gray market: the legal squeeze is now the headline, not a footnote. The Fifth Circuit ruling ends 503B mass compounding of GLP-1s outright, while 503A individualized compounding survives as the remaining channel. Separately, on What the Health Just Happened? (August 31), pharmacist Ben Epstein, a PharmD and former University of Florida faculty member commenting from outside the drugmakers, detailed the July 2026 FDA Pharmacy Compounding Advisory Committee vote, which "by narrow vote… voted yes to approve six" of roughly 19 category-2 peptides for the 503A bulk list (rejecting DSIP). For the thesis: the branded incumbents' pricing perimeter is tightening on the mass-production side, even as the individualized-compounding and peptide-wellness fringes keep finding new gaps.
• Obesity as "disease-modifying," the clinical case for lifelong, covered use kept building. On Rheumnow (September 4), Dr. Jack Cush, a rheumatologist and editor of Rheumnow.com, showed that obesity blunts other expensive drugs: higher BMI cut the response to JAK inhibitors step by step, with the ACR20 response dropping "6%" in overweight patients up to "22%" in the most obese. His conclusion: "treating obesity is disease-modifying therapy." DOC Updates (September 3) and CEimpact (August 31) extended the same logic into liver disease (MASH/MASLD, where roughly 10% weight loss can "move people back a stage") and the new cardiovascular-kidney-metabolic framework (where "nearly 90% of US adults have at least one" risk factor). Each of these is another door for label expansion and insured, guideline-driven volume.
• Medtech and bariatric: quiet. No dedicated bariatric-surgery or ortho read-through this week, and last issue's Stryker idea had no follow-up.

What changed vs last week

• Compounding flipped from a quality story to a legal resolution. Last week's compounding angle was the "secret shopper" study on sketchy online sellers. This week it's the Fifth Circuit ending 503B mass compounding outright, a structural, durable change to the pricing landscape rather than a color piece.
• The Medicare $50 program went from secondhand to sourced and quantified. Last week it came thirdhand from a platform CEO ("Medicare just launched its own $50 GLP-1 program… through 2027"). This week the hard mechanics arrived from a pharmacy director and a patient-advocate host: 600,000+ enrolled, started July 1, $50 a month against $1,000+ list, doesn't count toward the deductible (so roughly $600 a year), runs outside standard Part D, sunsets end-2027.
• The employer-pullback fear got named logos. Last week the payer worry was abstract ("less than 2% of covered members actually get access"). This week it's concrete: Starbucks and PepsiCo, by name, cutting or scrutinizing coverage, countered directly by Ricks's "more than break even by 12 months" study. The bull and bear payer fight is now an on-the-record argument.
• Confirmed and extended: The "Lilly is the leader" story got a CEO's own numbers (65% of the company, 25 to 30 million patients). The Gallup penetration figure moved from last week's "one in 10 adults" to this week's "11% currently / 15% ever" (Rheumnow), plus "one in five US households" (PwC via Daybreak). The persistence problem sharpened: last week's "40% of weight lost is muscle" became this week's "only about half still on therapy at one year" and "regain two-thirds within a year of stopping." Retatrutide's ~28% top-dose efficacy and the crowded-pipeline theme both held.
• New this week: the SURPASS cardiovascular approval for Mounjaro; Lilly's Morita Biosciences deal and $25B YTD M&A tally; "aluralintide" named as a pipeline asset; oral semaglutide 25mg confirmed approved for obesity with a MACE indication; CagriSema's timeline ("approval by end of the year," market "early 2028"); orforglipron's ATTAIN/MAINTAIN maintenance studies; the India generics case study; and the FDA's July peptide-compounding vote.
• Still quiet: Amgen MariTide, Viking VK2735, and Roche CT-388/CT-996 (a real multi-week gap now); UBT-251; Western contract manufacturers (CTLT, LNZA, TMO) and pen and injector suppliers (Ypsomed, Gerresheimer, Phillips Medisize) by name; Novo executive commentary and Capital Markets Day; the Tennessee Fair Rx Act and other specifically-named state statutes; and the label-expansion trials by name, with SUMMIT, ESSENCE, SURMOUNT-OSA, FLOW, and STEP-HFpEF all absent even as their disease areas (CVD, MASH, sleep apnea, CKD) were discussed generically. And still, every week: clean TRx/NRx counts times a real net price per script, the one dataset that would actually end the bull and bear fight.

The summary: two hard wins for the bull side, a court ruling that tightens supply and an FDA approval that widens the label, landed in the same week that named employers hardened the bear side and Washington swapped commercial rebates for a cheap fixed price. Volume up, price down, both faster. Same elephant, sharper tusks.